ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Railways
  • World
    • Economy
    • Politics
    • Markets
  • Survey
  • videos
  • photos
  • More ...
    • VIDEOS
    • PHOTOS
BREAKING NEWS
  • Dalal Street Corner: Softening crude, FIIs turning net buyers allow market to close on high note; what should investors do on Th
  • Gold Price Outlook: Yellow metal on slippery ground; experts give intraday trading strategy, outlook
  • Will oil prices surge to $380 or slump to $45—What JP Morgan, CITI reports say?
  • MF industry's asset base rises 14% to Rs 37.75 lakh cr in June quarter
  • TVS Motor drives in new bike 'Ronin' priced at Rs 1.49 lakh
Read in App
Business News » World News

Factbox - Bristol-Myers' $74 billion Celgene buy has investors looking for next deal

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App

Bristol-Myers Squibb Co`s announcement that it would buy Celgene Corp for $74 billion has raised investors` hopes that a wave of consolidation among drugmakers could be coming. The following are some of the companies in the sector whose shares rose on Thursday on takeover speculation following the deal announcement:INCYTE CORP , ENDED TRADING UP 7 PERCENT

The failure of an Incyte immunotherapy drug in combination with Merck & Co`s Keytruda in a melanoma trial last year sent its shares reeling. But analysts have said its bone marrow disorder treatment, Jakafi, has become a meaningful new revenue opportunity for the company. At a $15 billion market capitalisation, Incyte remains a digestible size for larger players such as Gilead Sciences Inc and Sanofi SA . RBC analyst Brian Abrahams said in a research note on Thursday that Incyte is an acquisition target because it is undervalued and has an oncology and inflammation pipeline. GILEAD SCIENCES INC , ENDED TRADING UP 3 PERCENT

Gilead has a hefty $85 billion market capitalisation, making it only a target for the largest global drugmakers. Its product portfolio targets HIV/AIDS, hepatitis C, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. The company recently named a new CEO, Daniel O`Day, who previously headed Roche Holdings AG`s pharmaceutical business. O`Day is expected to help Gilead build out its global presence, especially in liver disease beyond hepatitis C, oncology and inflammation. ALEXION PHARMACEUTICALS INC , ENDED TRADING UP 2 PERCENT

Rare disease specialist Alexion, which has faced pressure from activist hedge fund Elliott Management could be an acquisition target for companies such as Amgen Inc or Pfizer Inc
, analysts have said. Extremely expensive drugs for ultra rare diseases have become increasingly attractive to larger drugmakers. NASH COMPANIES

Raymond James analysts said in a research note that M&A could happen this year involving companies focussed on the huge unmet need for treating the progressive fatty liver disease known as NASH (non-alcoholic steatohepatitis), which does not yet have any approved treatments. Even though their shares did not get a boost on Thursday, Madrigal Pharmaceuticals and Intercept Pharmaceuticals are among the leaders developing treatments to tap a market that could eventually be worth $30 billion. As they race towards regulatory approval for NASH, these companies could become targets for larger biotechs. Allergan, for example, bought Tobira in 2016 for its experimental NASH drug for $1.8 billion, 19 times what the stock market was valuing the company. RBC`s investor survey showed Intercept, which was a market value of $2.8 billion, was a favored takeout candidate by investors for this year. Several other small companies are also developing promising NASH drugs.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Economy
Updated: Fri, Jan 04, 2019
04:30 am
Reuters
RELATED NEWS
Government notifies procedural changes in GST rules - details here Government notifies procedural changes in GST rules - details here
PM Modi inaugurates Digital India Week, hails technology for its role in the pandemic PM Modi inaugurates Digital India Week, hails technology for its role in the pandemic
Pricing flexibility, lower credit cost to help revive NBFC-MFIs profitability this fiscal: Report Pricing flexibility, lower credit cost to help revive NBFC-MFIs profitability this fiscal: Report
Crisil cuts FY23 GDP growth estimate to 7.3% Crisil cuts FY23 GDP growth estimate to 7.3%
US stocks see worst first half drop in over 50 years US stocks see worst first half drop in over 50 years

LATEST NEWS

Buy, Sell or Hold: What should investors do with Tube Investment, Saregama and Oil India?

Cos with over Rs 5 cr annual turnover will soon have to generate GST e-invoices for B2B transactions: Official

Stocks to buy today: List of 20 stocks for profitable trade on July 7

Anil Singhvi's strategy on July 7: Support zone on Nifty is 15850-15925 and Bank Nifty is 33950-34150

Stocks in news: GM Breweries, Torrent Pharma, Titan, HDFC Bank among other shares that may remain in focus today - Here's why

Stocks to buy: Sanjiv Bhasin picks Exide, GNFC for gains today; here's why

DEA Secretary Ajay Seth says RBI's well thought thorough measures keeping economy in good shape; says will impact foreign flows positively

Aviation Ministry issues draft notification for changes in aircraft rules - All you need to know

PT Usha, Ilaiyaraaja among four nominated to Rajya Sabha

Government restricts exports of flour, other derivatives from July 12

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
© 2022. India Dot Com Private Limited. All Rights Reserved.
LIVE TV